{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T10:01:48Z","timestamp":1772100108878,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11886-025-02202-1","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T05:21:47Z","timestamp":1737609707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Accuracy of Technetium-99\u00a0m Pyrophosphate Imaging in Diagnosing Transthyretin Cardiac Amyloidosis and Its Impact on Patient Management"],"prefix":"10.1007","volume":"27","author":[{"given":"Zainab","family":"Altaha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4676-2433","authenticated-orcid":false,"given":"Robert J. H.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"issue":"3","key":"2202_CR1","first-page":"322","volume":"36","author":"NM Fine","year":"2020","unstructured":"Fine NM, Davis MK, Anderson K, Delgado DH, Giraldeau G, Kitchlu A, et al. Canadian Cardiovascular Society\/Canadian Heart Failure Society Joint Position Statement on the evaluation and management of patients with Cardiac Amyloidosis. Can J Cardiol. 2020;36(3):322\u201334.","journal-title":"Can J Cardiol"},{"issue":"11","key":"2202_CR2","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"M Kittleson Michelle","year":"2023","unstructured":"Kittleson Michelle M, Ruberg Frederick L, Ambardekar Amrut V, Brannagan Thomas H, Cheng Richard K, et al. 2023 ACC Expert Consensus decision pathway on Comprehensive Multidisciplinary Care for the patient with Cardiac Amyloidosis. J Am Coll Cardiol. 2023;81(11):1076\u2013126.","journal-title":"J Am Coll Cardiol"},{"key":"2202_CR3","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijcard.2019.12.063","volume":"304","author":"B Ladefoged","year":"2020","unstructured":"Ladefoged B, Dybro A, Povlsen JA, Vase H, Clemmensen TS, Poulsen SH. Diagnostic delay in wild type transthyretin cardiac amyloidosis. Int J Cardiol. 2020;304:138\u201343.","journal-title":"Int J Cardiol"},{"issue":"24","key":"2202_CR4","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404\u201312.","journal-title":"Circulation"},{"issue":"2","key":"2202_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","volume":"6","author":"S Bokhari","year":"2013","unstructured":"Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195\u2013201.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"6","key":"2202_CR6","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.jcmg.2020.08.027","volume":"14","author":"J Poterucha Timothy","year":"2021","unstructured":"Poterucha Timothy J, Elias P, Bokhari S, Einstein Andrew J, DeLuca A, Kinkhabwala M, et al. Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m pyrophosphate. JACC Cardiovasc Imaging. 2021;14(6):1221\u201331.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"2202_CR7","doi-asserted-by":"publisher","first-page":"e010249","DOI":"10.1161\/CIRCIMAGING.119.010249","volume":"13","author":"A Masri","year":"2020","unstructured":"Masri A, Bukhari S, Ahmad S, Nieves R, Eisele YS, Follansbee W, et al. Efficient 1-Hour Technetium-99 m pyrophosphate imaging protocol for the diagnosis of Transthyretin Cardiac Amyloidosis. Circ Cardiovasc Imaging. 2020;13(2):e010249.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"5","key":"2202_CR8","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1007\/s12350-020-02139-8","volume":"27","author":"BW Sperry","year":"2020","unstructured":"Sperry BW, Burgett E, Bybee KA, McGhie AI, O\u2019Keefe JH, Saeed IM, et al. Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: imaging at 1 vs 3 hours and planar vs SPECT\/CT. J Nucl Cardiol. 2020;27(5):1802\u20137.","journal-title":"J Nucl Cardiol"},{"issue":"5","key":"2202_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.carpath.2016.07.001","volume":"25","author":"MA Stats","year":"2016","unstructured":"Stats MA, Stone JR. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovasc Pathol. 2016;25(5):413\u20137.","journal-title":"Cardiovasc Pathol"},{"key":"2202_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ijcard.2022.01.036","volume":"352","author":"U Thelander","year":"2022","unstructured":"Thelander U, Westermark GT, Antoni G, Estrada S, Zancanaro A, Ihse E, et al. Cardiac microcalcifications in transthyretin (ATTR) amyloidosis. Int J Cardiol. 2022;352:84\u201391.","journal-title":"Int J Cardiol"},{"issue":"4","key":"2202_CR11","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s12350-020-02455-z","volume":"28","author":"S Dorbala","year":"2021","unstructured":"Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, Addendum to ASNC\/AHA\/ASE\/EANM\/HFSA, et al. \/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2021;28(4):1769\u201374.","journal-title":"J Nucl Cardiol"},{"issue":"2","key":"2202_CR12","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s12350-022-02985-8","volume":"30","author":"BW Sperry","year":"2023","unstructured":"Sperry BW, Bateman TM, Akin EA, Bravo PE, Chen W, Dilsizian V, et al. Hot spot imaging in cardiovascular diseases: an information statement from SNMMI, ASNC, and EANM. J Nucl Cardiol. 2023;30(2):626\u201352.","journal-title":"J Nucl Cardiol"},{"issue":"4","key":"2202_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11886-018-0970-2","volume":"20","author":"W Chen","year":"2018","unstructured":"Chen W, Ton VK, Dilsizian V. Clinical phenotyping of Transthyretin Cardiac amyloidosis with bone-seeking Radiotracers in Heart failure with preserved ejection fraction. Curr Cardiol Rep. 2018;20(4):23.","journal-title":"Curr Cardiol Rep"},{"issue":"6","key":"2202_CR14","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1007\/s12350-023-03297-1","volume":"30","author":"N Ahluwalia","year":"2023","unstructured":"Ahluwalia N, Roshankar G, Draycott L, Jimenez-Zepeda V, Fine N, Chan D, et al. Diagnostic accuracy of bone scintigraphy imaging for transthyretin cardiac amyloidosis: systematic review and meta-analysis. J Nucl Cardiol. 2023;30(6):2464\u201376.","journal-title":"J Nucl Cardiol"},{"issue":"5","key":"2202_CR15","doi-asserted-by":"publisher","first-page":"e013829","DOI":"10.1161\/CIRCIMAGING.121.013829","volume":"15","author":"M Hussain","year":"2022","unstructured":"Hussain M, Krywanczyk A, Donnellan E, Martyn T, Hassan OA, Alkharabsheh S, et al. Association between Atrial Uptake on Cardiac Scintigraphy with Technetium-99m-Pyrophosphate labeled bone-seeking Tracers and Atrial Fibrillation. Circ Cardiovasc Imaging. 2022;15(5):e013829.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"2","key":"2202_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jacep.2021.11.016","volume":"8","author":"E Donnellan","year":"2022","unstructured":"Donnellan E, Hussain M, Jaber W, Patel Divyang R, Kanj M, Wazni O, et al. Atrial uptake of Technetium-99m-Pyrophosphate labeled bone-seeking Tracers is Associated with Post ablation Atrial Fibrillation recurrence. JACC Clin Electrophysiol. 2022;8(2):251\u20133.","journal-title":"JACC Clin Electrophysiol"},{"issue":"15","key":"2202_CR17","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.123.066524","volume":"149","author":"A Porcari","year":"2024","unstructured":"Porcari A, Fontana M, Canepa M, Biagini E, Cappelli F, Gagliardi C, et al. Clinical and prognostic implications of right ventricular uptake on bone scintigraphy in Transthyretin Amyloid Cardiomyopathy. Circulation. 2024;149(15):1157\u201368.","journal-title":"Circulation"},{"issue":"2 Pt 1","key":"2202_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jcmg.2017.06.020","volume":"11","author":"BW Sperry","year":"2018","unstructured":"Sperry BW, Vranian MN, Tower-Rader A, Hachamovitch R, Hanna M, Brunken R, et al. Regional Variation in Technetium Pyrophosphate Uptake in Transthyretin Cardiac Amyloidosis and Impact on Mortality. JACC Cardiovasc Imaging. 2018;11(2 Pt 1):234\u201342.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"2202_CR19","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1007\/s12350-023-03256-w","volume":"30","author":"C Akincioglu","year":"2023","unstructured":"Akincioglu C, Murthi M, Romsa J, Warrington J, Malhotra S. Comparison of cardio-focal and chest reconstruction of technetium-99m pyrophosphate scintigraphy for diagnosis of transthyretin cardiac amyloidosis: a quality assurance study. J Nucl Cardiol. 2023;30(6):2607\u201314.","journal-title":"J Nucl Cardiol"},{"key":"2202_CR20","doi-asserted-by":"crossref","unstructured":"Kaur S, Chamseddine F, Abadie B, Sunder V, Jaber W. Regional variation in technetium pyrophosphate (PYP) uptake in transthyretin cardiac amyloidosis (ATTR-CA) and concomitant myocardial infarction. J Nucl Cardiol. 2024:102031.","DOI":"10.1016\/j.nuclcard.2024.102031"},{"issue":"4","key":"2202_CR21","doi-asserted-by":"publisher","first-page":"652","DOI":"10.2967\/jnumed.122.264423","volume":"64","author":"RJH Miller","year":"2023","unstructured":"Miller RJH, Pieszko K, Shanbhag A, Feher A, Lemley M, Killekar A, et al. Deep learning coronary artery calcium scores from SPECT\/CT Attenuation maps improve prediction of major adverse cardiac events. J Nucl Med. 2023;64(4):652\u20138.","journal-title":"J Nucl Med"},{"issue":"6","key":"2202_CR22","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41569-022-00818-2","volume":"20","author":"K Sud","year":"2023","unstructured":"Sud K, Narula N, Aikawa E, Arbustini E, Pibarot P, Merlini G, et al. The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis. Nat Rev Cardiol. 2023;20(6):418\u201328.","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"2202_CR23","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1097\/RLU.0000000000005086","volume":"49","author":"ARP Nunes","year":"2024","unstructured":"Nunes ARP, Alves VM. Mitral annular calcification as a potential false-positive for Cardiac Amyloidosis in 99m Tc-DPD scintigraphy accurately identified by SPECT\/CT. Clin Nucl Med. 2024;49(4):e179\u201381.","journal-title":"Clin Nucl Med"},{"issue":"6","key":"2202_CR24","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1053\/j.sult.2010.10.001","volume":"31","author":"PE Kinahan","year":"2010","unstructured":"Kinahan PE, Fletcher JW. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR. 2010;31(6):496\u2013505.","journal-title":"Semin Ultrasound CT MR"},{"issue":"1","key":"2202_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40658-020-00342-7","volume":"8","author":"C Ren","year":"2021","unstructured":"Ren C, Ren J, Tian Z, Du Y, Hao Z, Zhang Z, et al. Assessment of cardiac amyloidosis with (99m)Tc-pyrophosphate (PYP) quantitative SPECT. EJNMMI Phys. 2021;8(1):3.","journal-title":"EJNMMI Phys"},{"issue":"1","key":"2202_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s41824-018-0035-1","volume":"2","author":"SC Ramsay","year":"2018","unstructured":"Ramsay SC, Lindsay K, Fong W, Patford S, Younger J, Atherton J. Tc-HDP quantitative SPECT\/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population. Eur J Hybrid Imaging. 2018;2(1):17.","journal-title":"Eur J Hybrid Imaging"},{"issue":"1","key":"2202_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s12350-022-02988-5","volume":"30","author":"JC Avalon","year":"2023","unstructured":"Avalon JC, Fuqua J, Deskins S, Miller T, Conte J, Martin D, et al. Quantitative single photon emission computed tomography derived standardized uptake values on 99mTc-PYP scan in patients with suspected ATTR cardiac amyloidosis. J Nucl Cardiol. 2023;30(1):127\u201339.","journal-title":"J Nucl Cardiol"},{"issue":"6","key":"2202_CR28","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.jcmg.2020.03.020","volume":"13","author":"PR Scully","year":"2020","unstructured":"Scully PR, Morris E, Patel KP, Treibel TA, Burniston M, Klotz E, et al. DPD quantification in Cardiac Amyloidosis: a novel imaging biomarker. JACC Cardiovasc Imaging. 2020;13(6):1353\u201363.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"2202_CR29","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s00259-022-06028-9","volume":"50","author":"JC Dickson","year":"2023","unstructured":"Dickson JC, Armstrong IS, Gabi\u00f1a PM, Denis-Bacelar AM, Krizsan AK, Gear JM, et al. EANM practice guideline for quantitative SPECT-CT. Eur J Nucl Med Mol Imaging. 2023;50(4):980\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"2202_CR30","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1007\/s12350-023-03353-w","volume":"30","author":"S Watanabe","year":"2023","unstructured":"Watanabe S, Nakajima K, Toshima F, Wakabayashi H, Yoshida S, Yoneyama H, et al. Transthyretin amyloid cardiomyopathy disease burden quantified using (99m)Tc-pyrophosphate SPECT\/CT: volumetric parameters versus SUVmax ratio at 1 and 3 hours. J Nucl Cardiol. 2023;30(6):2721\u201335.","journal-title":"J Nucl Cardiol"},{"issue":"1","key":"2202_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s12350-022-02960-3","volume":"30","author":"L Kessler","year":"2023","unstructured":"Kessler L, Fragoso Costa P, Kersting D, Jentzen W, Weber M, L\u00fcdike P, et al. Quantitative 99mTc-DPD-SPECT\/CT assessment of cardiac amyloidosis. J Nucl Cardiol. 2023;30(1):101\u201311.","journal-title":"J Nucl Cardiol"},{"issue":"10","key":"2202_CR32","doi-asserted-by":"publisher","first-page":"101261","DOI":"10.1016\/j.jacadv.2024.101261","volume":"3","author":"R Rettl","year":"2024","unstructured":"Rettl R, Calabretta R, Duca F, Kronberger C, Binder C, Willixhofer R, et al. DPD quantification correlates with Extracellular volume and Disease Severity in Wild-Type Transthyretin Cardiac Amyloidosis. JACC Adv. 2024;3(10):101261.","journal-title":"JACC Adv"},{"issue":"5","key":"2202_CR33","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2967\/jnumed.120.247312","volume":"62","author":"S Dorbala","year":"2021","unstructured":"Dorbala S, Park M-A, Cuddy S, Singh V, Sullivan K, Kim S, et al. Absolute quantitation of Cardiac 99mTc-Pyrophosphate using cadmium-zinc-telluride\u2013based SPECT\/CT. J Nucl Med. 2021;62(5):716\u201322.","journal-title":"J Nucl Med"},{"issue":"5","key":"2202_CR34","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s12350-021-02563-4","volume":"28","author":"RJH Miller","year":"2021","unstructured":"Miller RJH, Cadet S, Mah D, Pournazari P, Chan D, Fine NM, et al. Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis. J Nucl Cardiol. 2021;28(5):1835\u201345.","journal-title":"J Nucl Cardiol"},{"issue":"5","key":"2202_CR35","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1007\/s12350-021-02806-4","volume":"29","author":"G Roshankar","year":"2022","unstructured":"Roshankar G, White GC, Cadet S, Fine NM, Chan D, White JA, et al. Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosis. J Nucl Cardiol. 2022;29(5):2679\u201390.","journal-title":"J Nucl Cardiol"},{"issue":"1","key":"2202_CR36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13550-021-00828-0","volume":"11","author":"S Ben-Haim","year":"2021","unstructured":"Ben-Haim S, Chicheportiche A, Goshen E, Arad M, Smekhov M, Menezes LJ, et al. Quantitative SPECT\/CT parameters of myocardial (99m)Technetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) uptake in suspected cardiac transthyretin amyloidosis. EJNMMI Res. 2021;11(1):86.","journal-title":"EJNMMI Res"},{"key":"2202_CR37","doi-asserted-by":"crossref","unstructured":"Ahluwalia N, Roshankar G, Draycott L, Jimenez-Zepeda V, Fine N, Chan D, et al. Diagnostic accuracy of bone scintigraphy imaging for transthyretin cardiac amyloidosis: systematic review and meta-analysis. J Nucl Cardiol. 2023;30(6):2464-76.","DOI":"10.1007\/s12350-023-03297-1"},{"key":"2202_CR38","doi-asserted-by":"crossref","unstructured":"Maurer MS, Soman P, Hernandez A, Garcia-Pavia P, Signorovitch J, Wei LJ et al. Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings. Adv Ther. 2024;41(7):2723-42.","DOI":"10.1007\/s12325-024-02891-0"},{"issue":"11","key":"2202_CR39","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316.","journal-title":"N Engl J Med"},{"issue":"2","key":"2202_CR40","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and safety of Acoramidis in Transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(2):132\u201342.","journal-title":"N Engl J Med"},{"issue":"17","key":"2202_CR41","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","volume":"389","author":"MS Maurer","year":"2023","unstructured":"Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, et al. Patisiran Treatment in patients with Transthyretin Cardiac Amyloidosis. N Engl J Med. 2023;389(17):1553\u201365.","journal-title":"N Engl J Med"},{"issue":"8","key":"2202_CR42","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/ehjci\/jead030","volume":"24","author":"R Rettl","year":"2023","unstructured":"Rettl R, Wollenweber T, Duca F, Binder C, Cherouny B, Dachs T-M, et al. Monitoring tafamidis treatment with quantitative SPECT\/CT in transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2023;24(8):1019\u201330.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1","key":"2202_CR43","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","volume":"14","author":"M Fontana","year":"2021","unstructured":"Fontana M, Martinez-Naharro A, Chacko L, Rowczenio D, Gilbertson JA, Whelan CJ, et al. Reduction in CMR Derived Extracellular volume with Patisiran indicates cardiac amyloid regression. JACC Cardiovasc Imaging. 2021;14(1):189\u201399.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"2202_CR44","doi-asserted-by":"publisher","first-page":"e030512","DOI":"10.1161\/JAHA.123.030512","volume":"13","author":"AL Yu","year":"2024","unstructured":"Yu AL, Chen YC, Tsai CH, Wu YKA, Su MY, Chou CH, et al. Use of Technetium-99m\u2010Pyrophosphate single\u2010Photon Emission computed Tomography\/Computed tomography in monitoring therapeutic changes of Eplontersen in patients with Hereditary Transthyretin amyloid cardiomyopathy. J Am Heart Ass. 2024;13(2):e030512.","journal-title":"J Am Heart Ass"},{"key":"2202_CR45","doi-asserted-by":"publisher","first-page":"102019","DOI":"10.1016\/j.nuclcard.2024.102019","volume":"39","author":"S Vijayakumar","year":"2024","unstructured":"Vijayakumar S, Pabon AR, Clerc OF, Cuddy SAM, Gu Y, Watts C, et al. Quantitative 99mTc-pyrophosphate myocardial uptake: changes on transthyretin stabilization therapy. J Nucl Cardiol. 2024;39:102019.","journal-title":"J Nucl Cardiol"},{"issue":"4","key":"2202_CR46","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1007\/s12350-022-02977-8","volume":"29","author":"RJH Miller","year":"2022","unstructured":"Miller RJH, Huang C, Liang JX, Slomka PJ. Artificial intelligence for disease diagnosis and risk prediction in nuclear cardiology. J Nucl Cardiol. 2022;29(4):1754\u201362.","journal-title":"J Nucl Cardiol"},{"issue":"8","key":"2202_CR47","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.jcmg.2023.01.014","volume":"16","author":"MA Delbarre","year":"2023","unstructured":"Delbarre MA, Girardon F, Roquette L, Blanc-Durand P, Hubaut MA, Hachulla \u00c9, et al. Deep learning on bone scintigraphy to detect abnormal Cardiac Uptake at Risk of Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2023;16(8):1085\u201395.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"2202_CR48","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1016\/S2589-7500(23)00265-0","volume":"6","author":"CP Spielvogel","year":"2024","unstructured":"Spielvogel CP, Haberl D, Mascherbauer K, Ning J, Kluge K, Traub-Weidinger T, et al. Diagnosis and prognosis of abnormal cardiac scintigraphy uptake suggestive of cardiac amyloidosis using artificial intelligence: a retrospective, international, multicentre, cross-tracer development and validation study. Lancet Digit Health. 2024;6(4):e251\u201360.","journal-title":"Lancet Digit Health"},{"issue":"7","key":"2202_CR49","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.jcmg.2024.01.006","volume":"17","author":"JH Miller Robert","year":"2024","unstructured":"Miller Robert JH, Shanbhag A, Killekar A, Lemley M, Bednarski B, Kavanagh Paul B, et al. AI-Defined cardiac anatomy improves risk stratification of Hybrid Perfusion Imaging. JACC Cardiovasc Imaging. 2024;17(7):780\u201391.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"7","key":"2202_CR50","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.2967\/jnumed.124.267542","volume":"65","author":"RJH Miller","year":"2024","unstructured":"Miller RJH, Shanbhag A, Michalowska AM, Kavanagh P, Liang JX, Builoff V, et al. Deep learning-enabled quantification of (99m)Tc-Pyrophosphate SPECT\/CT for Cardiac Amyloidosis. J Nucl Med. 2024;65(7):1144\u201350.","journal-title":"J Nucl Med"},{"key":"2202_CR51","doi-asserted-by":"publisher","first-page":"101809","DOI":"10.1016\/j.nuclcard.2024.101809","volume":"33","author":"A Bhattaru","year":"2024","unstructured":"Bhattaru A, Rojulpote C, Vidula M, Duda J, Maclean MT, Swago S, et al. Deep learning approach for automated segmentation of myocardium using bone scintigraphy single-photon emission computed tomography\/computed tomography in patients with suspected cardiac amyloidosis. J Nucl Cardiol. 2024;33:101809.","journal-title":"J Nucl Cardiol"},{"issue":"11","key":"2202_CR52","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.jcmg.2023.09.002","volume":"16","author":"M Pelletier-Galarneau","year":"2023","unstructured":"Pelletier-Galarneau M, Dilsizian V. Shining a radiant light on Cardiac Amyloidosis with Novel 124I-Evuzamitide PET Imaging\u2217. JACC Cardiovasc Imaging. 2023;16(11):1449\u201351.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"11","key":"2202_CR53","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s11886-024-02114-6","volume":"26","author":"AJ Romero Pab\u00f3n","year":"2024","unstructured":"Romero Pab\u00f3n AJ, Clerc OF, Vijayakumar S, Cuddy SAM, Dorbala S. Recent advances in Positron Emission Tomography Radiotracers to Image Cardiac Amyloidosis. Curr Cardiol Rep. 2024;26(11):1153\u201362.","journal-title":"Curr Cardiol Rep"},{"key":"2202_CR54","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.2967\/jnumed.122.264866","volume":"64","author":"S Dorbala","year":"2023","unstructured":"Dorbala S, Kijewski MF. Molecular imaging of systemic and cardiac amyloidosis: recent advances and focus on the future. J Nucl Med. 2023;64:S20\u20138.","journal-title":"J Nucl Med"},{"issue":"6","key":"2202_CR55","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.jcmg.2020.02.025","volume":"13","author":"SAM Cuddy","year":"2020","unstructured":"Cuddy SAM, Bravo PE, Falk RH, El-Sady S, Kijewski MF, Park M-A, et al. Improved quantification of cardiac amyloid burden in systemic light chain amyloidosis: redefining early Disease? JACC Cardiovasc Imaging. 2020;13(6):1325\u201336.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"2202_CR56","doi-asserted-by":"publisher","first-page":"e0301756","DOI":"10.1371\/journal.pone.0301756","volume":"19","author":"SJ Kennel","year":"2024","unstructured":"Kennel SJ, Jackson JW, Stuckey A, Richey T, Foster JS, Wall JS. Preclinical evaluation of Tc-99m p5\u2009+\u200914 peptide for SPECT detection of cardiac amyloidosis. PLoS ONE. 2024;19(4):e0301756.","journal-title":"PLoS ONE"},{"issue":"1","key":"2202_CR57","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2967\/jnumed.124.267869","volume":"66","author":"RJH Miller","year":"2025","unstructured":"Miller RJH, Patel KK, Kwiecinski J, Slipczuk L, Dweck M, Newby DE, et al. Nuclear cardiology surrogate biomarkers in clinical trials. J Nucl Med. 2025;66(1):4\u201311.","journal-title":"J Nucl Med"},{"issue":"6","key":"2202_CR58","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1007\/s12350-022-03089-z","volume":"29","author":"MH Al-Mallah","year":"2022","unstructured":"Al-Mallah MH, Bateman TM, Branch KR, Crean A, Gingold EL, Thompson RC, et al. 2022 ASNC\/AAPM\/SCCT\/SNMMI guideline for the use of CT in hybrid nuclear\/CT cardiac imaging. J Nucl Cardiol. 2022;29(6):3491\u2013535.","journal-title":"J Nucl Cardiol"},{"issue":"1","key":"2202_CR59","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, et al. Vutrisiran in patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med. 2025;392(1):33\u201344.","journal-title":"N Engl J Med"},{"issue":"10","key":"2202_CR60","first-page":"S69","volume":"37","author":"M Maurer","year":"2021","unstructured":"Maurer M, Kristen A, Benson M, Falk R, Buchele G, Brambatti M, et al. Evaluation of the efficacy and safety of IONIS-TTR-LRX in patients with transthyretin-mediated amyloid cardiomyopathy: the Cardio-Ttransform Study. Can J Cardiol. 2021;37(10):S69.","journal-title":"Can J Cardiol"},{"issue":"3","key":"2202_CR61","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2303765","volume":"389","author":"P Garcia-Pavia","year":"2023","unstructured":"Garcia-Pavia P, Siepen Fad, Donal E, Lairez O, Meer Pvd, Kristen AV, et al. Phase 1 trial of antibody NI006 for depletion of Cardiac Transthyretin amyloid. N Engl J Med. 2023;389(3):239\u201350.","journal-title":"N Engl J Med"},{"issue":"11","key":"2202_CR62","first-page":"1433","volume":"16","author":"JS Wall","year":"2023","unstructured":"Wall JS, Martin EB, Lands R, Ramchandren R, Stuckey A, Heidel RE, et al. Cardiac amyloid detection by PET\/CT Imaging of Iodine (124I) evuzamitide (124I-p5\u2009+\u200914): a phase 1\/2 study. JACC: Cardiovasc Imaging. 2023;16(11):1433\u201348.","journal-title":"JACC: Cardiovasc Imaging"},{"issue":"8","key":"2202_CR63","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jcmg.2024.05.002","volume":"17","author":"OF Clerc","year":"2024","unstructured":"Clerc OF, Datar Y, Cuddy SAM, Bianchi G, Taylor A, Benz DC, et al. Prognostic Value of Left Ventricular 18F-Florbetapir uptake in systemic light-chain amyloidosis. JACC Cardiovasc Imaging. 2024;17(8):911\u201322.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"2202_CR64","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2967\/jnumed.111.102053","volume":"54","author":"G Antoni","year":"2013","unstructured":"Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsj\u00f6 L, et al. In vivo visualization of amyloid deposits in the heart with 11\u00a0C-PIB and PET. J Nucl Med. 2013;54(2):213\u201320.","journal-title":"J Nucl Med"},{"issue":"6","key":"2202_CR65","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.jcmg.2020.02.023","volume":"13","author":"S Rosengren","year":"2020","unstructured":"Rosengren S, Skibsted Clemmensen T, Tolbod L, Granstam SO, Eiskj\u00e6r H, Wikstr\u00f6m G, et al. Diagnostic accuracy of [(11)C]PIB Positron Emission Tomography for detection of Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2020;13(6):1337\u201347.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2202_CR66","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00259-019-04290-y","volume":"46","author":"M Kircher","year":"2019","unstructured":"Kircher M, Ihne S, Brumberg J, Morbach C, Knop S, Kort\u00fcm KM, et al. Detection of cardiac amyloidosis with 18 F-Florbetaben-PET\/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy. Eur J Nucl Med Mol Imaging. 2019;46:1407\u201316.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2202_CR67","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/13506129.2020.1760237","volume":"27","author":"S M\u00f6ckelind","year":"2020","unstructured":"M\u00f6ckelind S, Axelsson J, Pilebro B, Lindqvist P, Suhr OB, Sundstr\u00f6m T. Quantification of cardiac amyloid with [18F]Flutemetamol in patients with V30M hereditary transthyretin amyloidosis. Amyloid. 2020;27(3):191\u20139.","journal-title":"Amyloid"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02202-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-025-02202-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02202-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:03:24Z","timestamp":1772096604000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-025-02202-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2202"],"URL":"https:\/\/doi.org\/10.1007\/s11886-025-02202-1","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"14 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Dr. Miller receives research and consulting support from Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"37"}}